Source: Nasdaq

ADMA Biologics: FDA Approves ADMA Biologics' Innovative Production Yield Enhancement Process

(RTTNews) - ADMA Biologics, Inc. (ADMA) Monday said that the United States Food and Drug Administration (FDA) has approved the company's innovative production yield enhancement process.

Read full article »

ADMA Biologics's Competitors | ADMA Biologics's News | ADMA Biologics's Financials

Followers on Owler

1,068

Annual Revenue

$100-500M

Employees

500-1.0K

President & CEO

Adam S. Grossman

CEO Approval Rating

90/100

ADMA Biologics is a New Jersey-based biopharmaceutical company that researches and develops plasma-derived products for the treatment of infectious diseases.